Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Cisplatin Combination Expansion:~Arm 1:Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting; Arm 2: Patients with TNBC and one or two prior cytotoxic therapies in the metastatic setting.~* Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination.~* Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination.~* Arm C: Her2+ breast cancer refractory to prior herceptin or lapatinib, her2+ esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch cancer that are candidates for treatment with a dacomitinib-based combination.~* Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.~* Eastern Cooperative Oncology Group \[ECOG\] performance must be 0 or 1.~* Adequate bone marrow, renal and liver function.~Exclusion Criteria:~* Prior therapy for Cisplatin Combination Expansion:~  * Prior platinum (carboplatin or cisplatin) in either the adjuvant or metastatic setting;~ * Prior radiation to \>25% bone marrow as estimated by the Investigator.~* Patients with known symptomatic brain metastases.~* Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the lead-in dose.~* Major surgery within 4 weeks of the baseline disease assessments.~* \>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.~* Active bacterial, fungal or viral infection.~* Uncontrolled or significant cardiovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: EXPERIMENTAL): None
- Arm C (Type: EXPERIMENTAL): None
- Expansion Arm 1 (Type: EXPERIMENTAL): None
- Expansion Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).